Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1977 1
1981 2
1982 1
1984 3
1986 1
1987 1
1988 5
1989 1
1990 7
1991 5
1992 4
1993 4
1994 6
1995 5
1996 12
1997 9
1998 13
1999 9
2000 7
2001 5
2002 7
2003 5
2004 5
2005 5
2006 7
2007 10
2008 4
2009 6
2010 9
2011 8
2012 8
2013 19
2014 40
2015 41
2016 42
2017 37
2018 38
2019 40
2020 50
2021 60
2022 38
2023 48
2024 63
2025 55
2026 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

710 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Herbst RS, et al. N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. N Engl J Med. 2020. PMID: 32997907 Clinical Trial.
Overall survival (primary end point) was tested hierarchically according to PD-L1 expression status among patients in the intention-to-treat population whose tumors were wild-type with respect to EGFR mutations or ALK translocations. Within the population with EGFR and ALK …
Overall survival (primary end point) was tested hierarchically according to PD-L1 expression status among patients in the intention-to-treat …
Bacteria induce skin regeneration via IL-1β signaling.
Wang G, Sweren E, Liu H, Wier E, Alphonse MP, Chen R, Islam N, Li A, Xue Y, Chen J, Park S, Chen Y, Lee S, Wang Y, Wang S, Archer NK, Andrews W, Kane MA, Dare E, Reddy SK, Hu Z, Grice EA, Miller LS, Garza LA. Wang G, et al. Cell Host Microbe. 2021 May 12;29(5):777-791.e6. doi: 10.1016/j.chom.2021.03.003. Epub 2021 Apr 1. Cell Host Microbe. 2021. PMID: 33798492 Free PMC article.
WIHN levels and stem cell markers correlate with bacterial counts, being lowest in germ-free (GF), intermediate in conventional specific pathogen-free (SPF), and highest in wild-type mice, even those infected with pathogenic Staphylococcus aureus. Reducing skin microbiota …
WIHN levels and stem cell markers correlate with bacterial counts, being lowest in germ-free (GF), intermediate in conventional specific pat …
EXO1 protects BRCA1-deficient cells against toxic DNA lesions.
van de Kooij B, Schreuder A, Pavani R, Garzero V, Uruci S, Wendel TJ, van Hoeck A, San Martin Alonso M, Everts M, Koerse D, Callen E, Boom J, Mei H, Cuppen E, Luijsterburg MS, van Vugt MATM, Nussenzweig A, van Attikum H, Noordermeer SM. van de Kooij B, et al. Mol Cell. 2024 Feb 15;84(4):659-674.e7. doi: 10.1016/j.molcel.2023.12.039. Epub 2024 Jan 23. Mol Cell. 2024. PMID: 38266640 Free PMC article.
EXO1 deficiency generates poly(ADP-ribose)-decorated DNA lesions during S phase that associate with unresolved DSBs and genomic instability in BRCA1-deficient but not in wild-type or BRCA2-deficient cells. Our data indicate that BRCA1/EXO1 double-deficient cells accumulate …
EXO1 deficiency generates poly(ADP-ribose)-decorated DNA lesions during S phase that associate with unresolved DSBs and genomic instability …
Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs.
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, Liu ACH, Yang Y, Wang V, Maher A, Grignano E, Reisz JA, D'Alessandro A, Young K, Wu Y, Fiumara M, Ferrari S, Naldini L, Gaiti F, Pai S, Egan G, Schimmer AD, Bader GD, Dick JE, Xie SZ, Trowbridge JJ, Chan SM. Hosseini M, et al. Nature. 2025 Jun;642(8067):421-430. doi: 10.1038/s41586-025-08871-w. Epub 2025 Apr 16. Nature. 2025. PMID: 40240595 Free PMC article.
Clonal haematopoiesis arises when a haematopoietic stem cell (HSC) acquires a mutation that confers a competitive advantage over wild-type HSCs, resulting in its clonal expansion. Individuals with clonal haematopoiesis are at increased risk of developing haematologic neopl …
Clonal haematopoiesis arises when a haematopoietic stem cell (HSC) acquires a mutation that confers a competitive advantage over wild …
Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
Helms AS, Davis FM, Coleman D, Bartolone SN, Glazier AA, Pagani F, Yob JM, Sadayappan S, Pedersen E, Lyons R, Westfall MV, Jones R, Russell MW, Day SM. Helms AS, et al. Circ Cardiovasc Genet. 2014 Aug;7(4):434-43. doi: 10.1161/CIRCGENETICS.113.000448. Epub 2014 Jul 16. Circ Cardiovasc Genet. 2014. PMID: 25031304 Free PMC article.
For truncating mutations in MYBPC3, the average ratio of mutant:wild-type transcripts was 1:5, in contrast to 1:1 for all sarcomere missense mutations, confirming that nonsense transcripts are uniquely unstable. ...By absolute quantification of abundance with multiple re …
For truncating mutations in MYBPC3, the average ratio of mutant:wild-type transcripts was 1:5, in contrast to 1:1 for all sarcomere …
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.
Brandi P, Conejero L, Cueto FJ, Martínez-Cano S, Dunphy G, Gómez MJ, Relaño C, Saz-Leal P, Enamorado M, Quintas A, Dopazo A, Amores-Iniesta J, Del Fresno C, Nistal-Villán E, Ardavín C, Nieto A, Casanovas M, Subiza JL, Sancho D. Brandi P, et al. Cell Rep. 2022 Jan 4;38(1):110184. doi: 10.1016/j.celrep.2021.110184. Cell Rep. 2022. PMID: 34986349 Free PMC article.
Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. ...
Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking func …
Charting the single-cell and spatial landscape of IDH-wild-type glioblastoma with GBmap.
Ruiz-Moreno C, Salas SM, Samuelsson E, Minaeva M, Ibarra I, Grillo M, Brandner S, Roy A, Forsberg-Nilsson K, Kranendonk MEG, Theis FJ, Nilsson M, Stunnenberg HG. Ruiz-Moreno C, et al. Neuro Oncol. 2025 Oct 14;27(9):2281-2295. doi: 10.1093/neuonc/noaf113. Neuro Oncol. 2025. PMID: 40312969 Free PMC article.
BACKGROUND: Glioblastoma (GB), particularly IDH-wild type, is the most aggressive brain malignancy with a dismal prognosis. Despite advances in molecular profiling, the complexity of its tumor microenvironment and spatial organization remains poorly understood. ...
BACKGROUND: Glioblastoma (GB), particularly IDH-wild type, is the most aggressive brain malignancy with a dismal prognosis. Despite a …
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD. Lane T, et al. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Circulation. 2019. PMID: 31109193
We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditary forms of the disease. METHODS: We studied 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V122 …
We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditar …
m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis.
Cieśla M, Ngoc PCT, Muthukumar S, Todisco G, Madej M, Fritz H, Dimitriou M, Incarnato D, Hellström-Lindberg E, Bellodi C. Cieśla M, et al. Mol Cell. 2023 Apr 6;83(7):1165-1179.e11. doi: 10.1016/j.molcel.2023.02.024. Epub 2023 Mar 20. Mol Cell. 2023. PMID: 36944332 Free article.
Although tumorigenic SF3B1 mutations have been extensively characterized, the role of "non-mutated" wild-type SF3B1 in cancer remains largely unresolved. Here, we identify a conserved epitranscriptomic program that steers SF3B1 levels to counteract leukemogenesis. ...
Although tumorigenic SF3B1 mutations have been extensively characterized, the role of "non-mutated" wild-type SF3B1 in cancer remains …
Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation.
Methven Jeknić S, Ahn-Horst TA, Ji AX, Ju JH, Paull M, Ji SG, Sinha U. Methven Jeknić S, et al. CPT Pharmacometrics Syst Pharmacol. 2026 Jun;15(6):e70277. doi: 10.1002/psp4.70277. CPT Pharmacometrics Syst Pharmacol. 2026. PMID: 42257495 Free PMC article.
The model showed that monomer efflux is nearly twice as high in hereditary ATTR-CM (ATTRv) as in wild-type ATTR-CM (ATTRwt). Comparison of treatment modalities showed that acoramidis yields the greatest reduction in monomer efflux (96% in ATTRwt, 95% in ATTRv) due to rapid …
The model showed that monomer efflux is nearly twice as high in hereditary ATTR-CM (ATTRv) as in wild-type ATTR-CM (ATTRwt). Comparis …
710 results